|Bid||12.68 x 3000|
|Ask||14.47 x 800|
|Day's Range||13.53 - 14.07|
|52 Week Range||8.27 - 17.62|
|Beta (3Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.67|
came up Wednesday night in the "Lightning Round" of Jim Cramer's entertaining and informative Mad Money program. Cramer said, "I think this one is really good. On-Balance-Volume (OBV) line turned stronger in late December.
The latest earnings announcement Amicus Therapeutics, Inc. (NASDAQ:FOLD) released in December 2018 confirmed that losses became smaller relative to the prior year's level as a result of recent tailwinds BelowRead More...
Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients.
NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Amicus Therapeutics, Inc. (NASDAQ: FOLD ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 ...
In another boost to Philadelphia’s standing as a cell and gene therapy hub, Cranbury, New Jersey-based Amicus Therapeutics said Tuesday it is establishing a new global research and gene therapy center at uCity Square, where the company expects to have 200 employees over the next few years. Amicus will occupy the top three floors — a total of 75,000-square-foot — at the new University City Science Center building at 3675 Market Street. An initial group of a couple dozen company employees has already moved into temporary space within the same complex at BioLabs@CIC Philadelphia.
Amicus Therapeutics (FOLD) today announced it is establishing a new Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its commitment to world-class science that makes a meaningful difference in the lives of people living with rare metabolic diseases. Philadelphia is a well-regarded ecosystem for biotechnology and gene therapy research and offers an ideal environment for Amicus to advance its pipeline, attract and retain top talent and foster external collaborations within the rare diseases.
Amicus Therapeutics (FOLD) today announced that the U.S. Food and Drug Administration (FDA) has granted to Amicus a Breakthrough Therapy Designation (“BTD”) to AT-GAA for the treatment of late onset Pompe disease, an inherited lysosomal storage disorder caused by the deficiency of an enzyme known as acid alpha-glucosidase (GAA). AT-GAA is the first ever investigational product for Pompe disease to receive BTD.
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CRANBURY, N.J., Feb. 12, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February.
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. Patients treated with AT-GAA for up to 24 months showed improvements in six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage and disease substrate. An additional poster2 with detailed results for the non-ambulatory cohort in the ATB200-02 study is also part of this afternoon’s poster session.
The biotech sector, home builders and small-caps overall were some of the strongest performers in the market last month. While not as cheap as they were to begin the year, there are a bevy of small- and mid-cap stocks that still look like they could rally further. With a market cap just over $2 billion, I would not be surprised to see Amicus acquired by a larger player at some point.
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...
Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.
CRANBURY, N.J., Jan. 18, 2019 -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare.
NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...
Amicus' shares crumbled with the broader market's decline last month, but the biotech has staged a stunning rally during the first few weeks of trading in 2019.
NEW YORK, Jan. 10, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.